Damora Therapeutics, Inc. (DMRA)
DMRA Stock Price Chart
Explore Damora Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DMRA price movements and trends.
DMRA Company Profile
Discover essential business fundamentals and corporate details for Damora Therapeutics, Inc. (DMRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Mar 2026
Employees
7.00
Website
https://www.damoratx.comCEO
Jennifer A. Jarrett
Description
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
DMRA Financial Timeline
Browse a chronological timeline of Damora Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.38.
Earnings released on 12 May 2026
EPS came in at -$0.62 falling short of the estimated -$0.21 by -195.24%.
Earnings released on 18 Mar 2026
EPS came in at -$3.24 falling short of the estimated -$0.14 by -2.22k%.
Earnings released on 5 Aug 2025
EPS came in at -$2.60 .
Earnings released on 8 May 2025
EPS came in at -$1.92 .
DMRA Stock Performance
Access detailed DMRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
